-
Eurofarma Invests in Abcuro as Part of $100 Million Disruptive Startups and Biotech Initiative
•
Brazil-based multinational company (MNC) Eurofarma has announced an investment in US immunotherapy developer Abcuro as part of a broader program to invest up to USD 100 million in potentially disruptive startups and biotechnology companies in the discovery and development phase. This 5-year project aims to support up to 25 companies…
